Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
NBRV was delisted on the 31st of July, 2023.
45 hedge funds and large institutions have $135M invested in Nabriva Therapeutics plc Ordinary Shares Ireland in 2017 Q4 according to their latest regulatory filings, with 19 funds opening new positions, 9 increasing their positions, 5 reducing their positions, and 14 closing their positions.
377% more call options, than puts
Call options by funds: $62K | Put options by funds: $13K
80% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 5
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
36% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 14
10% more funds holding
Funds holding: 41 → 45 (+4)
22% less capital invested
Capital invested by funds: $173M → $135M (-$38.4M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$5.49M |
| 2 |
Renaissance Technologies
New York
|
+$1.15M |
| 3 |
ACP
Acuta Capital Partners
Redwood City,
California
|
+$1.14M |
| 4 |
BlackRock
New York
|
+$1.13M |
| 5 |
Goldman Sachs
New York
|
+$674K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$7.91M |
| 2 |
PVI
Pura Vida Investments
New York
|
-$3.48M |
| 3 |
LCM
Laurion Capital Management
New York
|
-$2.59M |
| 4 |
NFA
Nationwide Fund Advisors
Columbus,
Ohio
|
-$1.45M |
| 5 |
WMSA
Weiss Multi-Strategy Advisers
New York
|
-$819K |
NBRV Hedge Fund Activity: Q4 2017 in Review
45 of the 4,410 institutional investors tracked by Wall St. Rank reported a position in Nabriva Therapeutics plc Ordinary Shares Ireland (NBRV) for Q4 2017, worth a combined $135M — down 22% from $173M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new NBRV positions and 14 closed out — a net gain of 5 holders — while 9 added to existing stakes and 5 trimmed.
The largest buyer was Millennium Management, opening a new position worth an estimated $5.49M. The largest seller was Morgan Stanley, cutting an estimated $7.91M.
- 45 institutional investors held Nabriva Therapeutics plc Ordinary Shares Ireland (NBRV) as of Q4 2017, up from 41 in Q3 2017.
- Funds reported $135M of Nabriva Therapeutics plc Ordinary Shares Ireland stock for Q4 2017, down 22% quarter-over-quarter.
- 19 funds opened new Nabriva Therapeutics plc Ordinary Shares Ireland positions in Q4 2017 and 14 closed out, a net change of +5 holders.
- The largest Nabriva Therapeutics plc Ordinary Shares Ireland buyer in Q4 2017 was Millennium Management, an estimated $5.49M added.
- The largest Nabriva Therapeutics plc Ordinary Shares Ireland seller in Q4 2017 was Morgan Stanley, an estimated $7.91M sold.
Based on aggregated 13F filings for Q4 2017.